Vincerx Pharma (NASDAQ:VINC) Shares Scheduled to Reverse Split on Tuesday, January 28th

Vincerx Pharma, Inc. (NASDAQ:VINC)’s stock is scheduled to reverse split on the morning of Tuesday, January 28th. The 1-20 reverse split was announced on Thursday, January 23rd. The number of shares owned by shareholders will be adjusted after the market closes on Monday, January 27th.

Vincerx Pharma Stock Down 19.4 %

Shares of NASDAQ:VINC traded down $0.03 during midday trading on Friday, hitting $0.10. 7,380,350 shares of the stock traded hands, compared to its average volume of 4,778,677. The business’s 50 day moving average is $0.22 and its two-hundred day moving average is $0.46. The stock has a market capitalization of $3.50 million, a PE ratio of -0.10 and a beta of 1.48. Vincerx Pharma has a one year low of $0.10 and a one year high of $9.37.

Analyst Ratings Changes

Separately, Leerink Partners lowered their price target on Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th.

Institutional Trading of Vincerx Pharma

A hedge fund recently raised its stake in Vincerx Pharma stock. Marshall Wace LLP lifted its stake in Vincerx Pharma, Inc. (NASDAQ:VINC) by 359.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 328,533 shares of the company’s stock after purchasing an additional 256,967 shares during the period. Marshall Wace LLP owned 1.11% of Vincerx Pharma worth $266,000 as of its most recent SEC filing. Institutional investors and hedge funds own 44.02% of the company’s stock.

About Vincerx Pharma

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.